MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

EnteroMedics Company Profile (NASDAQ:ETRM)

Consensus Ratings for EnteroMedics (NASDAQ:ETRM) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $16.00 (5,417.24% upside)

Analysts' Ratings History for EnteroMedics (NASDAQ:ETRM)
Show:
DateFirmActionRatingPrice TargetActions
6/9/2016Roth CapitalDowngradeBuy -> Neutral$3.00 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Canaccord GenuityLower Price Target$37.50 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015Craig HallumLower Price TargetBuy$75.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for EnteroMedics (NASDAQ:ETRM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q1($0.80)($0.94)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2016Q315($0.90)($0.95)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.10)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015Q414($0.10)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q3 14($0.10)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.10)($0.11)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014Q1 14($0.10)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2014Q413($0.10)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313($0.11)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q2 2013($0.13)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2013Q1 2013($0.13)($0.14)$0.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2013Q4 2012($0.14)($0.17)$0.36 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for EnteroMedics (NASDAQ:ETRM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.80)($0.05)($0.43)
Q2 20161($0.69)($0.69)($0.69)
Q3 20161($0.53)($0.53)($0.53)
Q4 20161($0.41)($0.41)($0.41)
(Data provided by Zacks Investment Research)
Dividend History for EnteroMedics (NASDAQ:ETRM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for EnteroMedics (NASDAQ:ETRM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/3/2016Peter M DelangeSVPBuy20,000$0.55$11,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Mark B KnudsonCEOBuy303,000$0.25$75,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Cathy FriedmanDirectorBuy11,800$1.70$20,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2014Luke EvninDirectorSell556,585$2.50$1,391,462.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2013Anthony P JanszDirectorBuy150,000$0.95$142,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for EnteroMedics (NASDAQ:ETRM)
DateHeadline
06/29/16 06:00 AMEnteroMedics Highlights Recent Patient Success with vBloc® Therapy in Combination with vBloc® Achieve Program - [PR Newswire] - ST. PAUL, Minn., June 29, 2016 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced a recent successful outcome following implantation of vBloc® Neurometabolic Therapy. The surgery was performed by Charles Procter, MD, Bariatric and General Surgeon at the Beltline Bariatric and Surgical Group in Atlanta, Georgia, where five vBloc procedures have been performed to date. After three months of treatment with vBloc Therapy and participation in vBloc® Achieve, the Company's comprehensive weight loss support program, the patient has lost approximately 25 pounds, and has had his Body Mass Index (BMI) reduced from 37.5 kg/m2 to 34 kg/m2.
06/28/16 08:47 AMCovering the Bases on EnteroMedics Inc. (NASDAQ:ETRM): Where is the Stock Going? - Press Telegraph
06/28/16 05:04 AMENTEROMEDICS INC Files SEC form 8-K, Other Events -
06/22/16 09:04 PMCan EnteroMedics Inc. (NASDAQ:ETRM) Meet Analysts Expectations? - Stocks Daily
06/22/16 09:04 PMStrong Buy Calls Count For EnteroMedics Inc. (NASDAQ:ETRM) At 1 - Investor Newswire
06/20/16 10:07 AMRoth Capital reported on (NASDAQ:ETRM) EnteroMedics Inc, cutting its stock price target to $1 earlier today
06/16/16 09:08 PMTrend Of Rating Given To EnteroMedics Inc. (NASDAQ:ETRM) - Investor Newswire
06/16/16 09:08 PMBrokers Issue Average Price Target Of 2.77 On EnteroMedics Inc. (ETRM) - Fiscal Standard
06/11/16 06:55 AMNASDAQ New Lows: Forbes Energy Services Ltd. (NASDAQ:FES), EnteroMedics Inc. (NASDAQ:ETRM), WL Ross ... - KC Register
06/10/16 07:01 AMEnteroMedics Cut By Roth Capital On Utilization Growth
06/09/16 03:57 PMEnteroMedics Cut By Roth Capital On Utilization Growth - Benzinga
06/09/16 07:52 AMEnteroMedics downgraded by ROTH Capital -
06/01/16 10:11 PMStrong Sell Calls Count For EnteroMedics Inc. (NASDAQ:ETRM) At 0 - Investor Newswire - Strong Sell Calls Count For EnteroMedics Inc. (NASDAQ:ETRM) At 0Investor NewswireThe Sell calls on EnteroMedics Inc. (NASDAQ:ETRM) were 0. Two months earlier 2 were the Strong Buy calls whereas Strong Sell calls were 0. During this period, the hold calls were 0. The buy recommendations were 0 and sell calls count was 0. Analyst ...EnteroMedics Inc. (NASDAQ:ETRM): Price Target ProjectionsNews Tribuneall 3 news articles »
06/01/16 06:13 AMEnteroMedics Announces First-of-its-Kind Procedure with vBloc® Therapy Used as Adjunctive Rescue Treatment for Failed Gastric Sleeve in Patients with Obesity - [at noodls] - ST. PAUL, Minn., June 1, 2016 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal ...
05/31/16 09:41 PMIs EnteroMedics Inc. (NASDAQ: ETRM)'s vBloc A Game-Changer? - Scibility Media - Scibility MediaIs EnteroMedics Inc. (NASDAQ: ETRM)'s vBloc A Game-Changer?Scibility MediaFor background, EnteroMedics Inc. (NASDAQ: ETRM) is engaged in the business of developing medical devices based on what is called neuroblocking technology. The devices are used to treat obesity and metabolic diseases among others. Therefore, vBloc ...Analyst Coverage: EnteroMedics Inc. (ETRM)Risers & Fallersall 2 news articles »
05/31/16 10:18 AMNext Weeks Broker Price Targets For EnteroMedics Inc. (ETRM) - Share Trading News - Next Weeks Broker Price Targets For EnteroMedics Inc. (ETRM)Share Trading NewsEnteroMedics Inc. has a 50 day moving average of 0.78 and a 200 day moving average of 1.38. The stock's market capitalization is 5.18M, it has a 52-week low of 0.55 and a 52-week high of 21.00. The share price of the company (ETRM) was down -9.68%, ...
05/24/16 01:52 PMEnteroMedics Inc. (NASDAQ:ETRM) Impact Score At 19 - Investor Newswire - EnteroMedics Inc. (NASDAQ:ETRM) Impact Score At 19Investor NewswireAlpha One explored various online articles released on EnteroMedics Inc. (NASDAQ:ETRM), and it set a daily sentiment score of 0 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content issued ...and more »
05/23/16 06:16 AMEnteroMedics to Host vBloc® Commercialization Update Conference Call - [at noodls] - ST. PAUL, Minn., May 23, 2016 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal ...
05/20/16 01:37 PMRevenue Update on EnteroMedics Inc(NASDAQ:ETRM) - Trade Calls - Revenue Update on EnteroMedics Inc(NASDAQ:ETRM)Trade CallsEnteroMedics Inc(NASDAQ:ETRM) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 5, 2016. Company reported revenue of $72.00K. Analysts estimated a revenue of $150.00K. Earnings per share ...Enteromedics Incorporated (NASDAQ:ETRM) Sellers Covered 5.05% of Their ShortsThe Postall 2 news articles »
05/19/16 01:14 PMInsiders Are Buying EnteroMedics Inc. (NASDAQ:ETRM) - Wall Street Hints and News - Insiders Are Buying EnteroMedics Inc. (NASDAQ:ETRM)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at EnteroMedics Inc. (NASDAQ:ETRM) have increased their position in the stock by 143.54%. Insiders now own 0.60% of total outstanding shares. There are both legal and illegal types of insider trading.and more »
05/13/16 04:09 PMENTEROMEDICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; -
05/11/16 07:12 AMConsensus Rating Review for EnteroMedics Inc. (NASDAQ:ETRM) - B.O.D.Y Confidential - Consensus Rating Review for EnteroMedics Inc. (NASDAQ:ETRM)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of EnteroMedics Inc. (NASDAQ:ETRM). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or ...and more »
05/11/16 07:12 AMEnteroMedics Inc. (NASDAQ:ETRM) Is $-20.26 Off Its 52-Week High - Stocks Daily - EnteroMedics Inc. (NASDAQ:ETRM) Is $-20.26 Off Its 52-Week HighStocks DailyThe technical analysis of EnteroMedics Inc. (NASDAQ:ETRM) stock indicates that it is trading $-0.15 points away -17.09% from its 50-day MA of $0.89. It is trading $-0.90 or -54.86% away its 200-day MA of $1.64. After the last close, the stock's price ...Enteromedics Incorporated (NASDAQ:ETRM) Sellers Covered 5.17% of Their ShortsFranklin Independentall 2 news articles »
05/10/16 04:18 PMENTEROMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers -
05/07/16 07:14 AMEnteromedics Reports Loss - Investment Is Still Highly Speculative - Seeking Alpha - Web Breaking NewsEnteromedics Reports Loss - Investment Is Still Highly SpeculativeSeeking AlphaThe few Enteromedics (NASDAQ:ETRM) retail investors left got yet another wake up call on the company when it reported its Q1 2016 financial results. The company posted a loss of $7.4 million or $0.94 per share. Sales for the entire quarter were $72,000.Analyst Coverage: EnteroMedics Inc. (ETRM)Risers & FallersEnteroMedics Inc (ETRM) Issues Earnings Results, Misses Expectations By $0.14 EPSWeb Breaking NewsEnteromedics Incorporated (NASDAQ:ETRM) Shorts Decreased by 5.17% After Short CoveringFranklin IndependentThe Wall Street Transcriptall 5 news articles »
05/06/16 07:45 AMEarnings Outlook on EnteroMedics Inc. (NASDAQ:ETRM) - B.O.D.Y Confidential - Earnings Outlook on EnteroMedics Inc. (NASDAQ:ETRM)B.O.D.Y ConfidentialAnalysts and investors will be anticipating EnteroMedics Inc. (NASDAQ:ETRM)'s next earnings release which is expected to be posted on or around 2016-05-05. Sell-side research firms on Wall Street are expecting that the company will post EPS of $-0.8 ...and more »
05/06/16 05:13 AMENTEROMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financial -
05/05/16 04:04 PMEnteroMedics Reports First Quarter 2016 Financial Results - [at noodls] - ST. PAUL, Minn., May 5, 2016 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal ...
05/05/16 07:35 AMAverage Analyst Rating for EnteroMedics Inc. (NASDAQ:ETRM) - B.O.D.Y Confidential - Average Analyst Rating for EnteroMedics Inc. (NASDAQ:ETRM)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on EnteroMedics Inc. (NASDAQ:ETRM) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/03/16 06:10 AMEnteroMedics Announces Closing of $6.25 Million Third Tranche of Previously-Announced Convertible Notes Offering - [at noodls] - ST. PAUL, Minn., May 3, 2016 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal ...
05/02/16 06:10 AMEnteroMedics Announces Exclusive Federal Government Business Channel Sales Agreement with Academy Medical to Provide vBloc® Neurometabolic Therapy to US Department of Veterans Affairs Medical Facilities - [at noodls] - ST. PAUL, Minn., May 2, 2016 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal ...
04/28/16 07:42 AMEnteroMedics Inc. (NASDAQ:ETRM) Wall Street Rating in Focus - News Tribune - EnteroMedics Inc. (NASDAQ:ETRM) Wall Street Rating in FocusNews TribuneZacks.com, founded by Len Zacks, a Mathematics Ph.D. from M.I.T. who discovered that earnings estimate revisions are the most powerful force impacting stock prices, track 2 equity research firms that cover shares of EnteroMedics Inc. (NASDAQ:ETRM).and more »
04/27/16 09:07 AMEnteroMedics Inc. (NASDAQ:ETRM) Share Rating Recap - B.O.D.Y Confidential - EnteroMedics Inc. (NASDAQ:ETRM) Share Rating RecapB.O.D.Y ConfidentialShares of EnteroMedics Inc. (NASDAQ:ETRM) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...
04/27/16 09:07 AMUpgrades And Downgrades For EnteroMedics Inc. (ETRM) - Risers & Fallers - Upgrades And Downgrades For EnteroMedics Inc. (ETRM)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of EnteroMedics Inc. (ETRM). The latest broker reports which are currently outstanding on Tuesday 26th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...
04/24/16 07:38 AMAfter Last Week What Do Analysts Think Of EnteroMedics Inc. (ETRM) - Share Trading News - After Last Week What Do Analysts Think Of EnteroMedics Inc. (ETRM)Share Trading NewsThe share price of EnteroMedics Inc. (ETRM) was down -8.08% during the last trading session, with a day high of 0.99. 105583 shares were traded on EnteroMedics Inc.'s last session. The stock's 50 day moving average is 0.99 and its 200 day moving ...
04/21/16 06:10 AMWeight Loss Surgery Foundation of America to Include EnteroMedics vBloc® Therapy as Part of the Grant Referral Program - [at noodls] - MINEOLA, N.Y. and ST. PAUL, Minn., April 21, 2016 /PRNewswire/ -- Weight Loss Surgery Foundation of America and EnteroMedics Inc. (NASDAQ: ETRM) announced today that Weight Loss Surgery Foundation of America ...
04/19/16 09:02 AMEnteromedics Incorporated (NASDAQ:ETRM) Sellers Increased By 0.73% Their Shorts - RiversideGazette.com - Enteromedics Incorporated (NASDAQ:ETRM) Sellers Increased By 0.73% Their ShortsRiversideGazette.comThe short interest to Enteromedics Incorporated's float is 11.77%. The stock decreased 3.22% or $0.03 on April 15, hitting $0.9. About 47,327 shares traded hands. EnteroMedics Inc (NASDAQ:ETRM) has declined 76.92% since September 10, 2015 and is ...and more »
04/19/16 09:02 AMEnteroMedics Inc. (NASDAQ:ETRM) Analyst Rating Review - Clinton Financial - EnteroMedics Inc. (NASDAQ:ETRM) Analyst Rating ReviewClinton FinancialCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 2 analysts that have provided ratings for EnteroMedics Inc. (NASDAQ:ETRM). 2 have rated the stock a “Strong ...and more »
04/14/16 01:04 PMEnteroMedics Inc. (NASDAQ:ETRM): Quick Look at Earnings - News Tribune - EnteroMedics Inc. (NASDAQ:ETRM): Quick Look at EarningsNews TribuneWhen EnteroMedics Inc. (NASDAQ:ETRM) issues their next quarterly report on or near 2016-05-05, Wall Street analysts are predicting they will report earnings per share of $-0.8. This consensus EPS number is provided by Zacks Research, which might differ ...and more »
04/14/16 01:04 PMEnteroMedics Flirting With Another Delisting Notice - Seeking Alpha - EnteroMedics Flirting With Another Delisting NoticeSeeking AlphaEnteroMedics' (NASDAQ:ETRM) investors are likely quite frustrated these days. Just 4 months after a 1-for-15 reverse split to solve NASDAQ listing requirements, the company finds itself once again trading below the $1.00 per share NASDAQ minimum.and more »
04/14/16 01:04 PMEarnings Watch on EnteroMedics Inc. (NASDAQ:ETRM) - RiversideGazette.com - Earnings Watch on EnteroMedics Inc. (NASDAQ:ETRM)RiversideGazette.comEnteroMedics Inc. (NASDAQ:ETRM) has a consensus earnings per share estimate for the current quarter of $-0.8 based on compiled analyst projections. The company is next expected to release earnings on or around 2016-05-05 for the period ending ...and more »
04/12/16 11:40 AMSales Of $24.375 Is Expected For EnteroMedics Inc. (NASDAQ:ETRM) - Investor Newswire - Sales Of $24.375 Is Expected For EnteroMedics Inc. (NASDAQ:ETRM)Investor NewswireThe mean of the annual revenue estimate of EnteroMedics Inc. (NASDAQ:ETRM) is $24.375 and the median is $24.375 as anticipated by 1 analysts for the period ended 4. The highest estimate is set at $24.375 while lowest projection stands at $24.375.
04/12/16 11:40 AMEnteroMedics Inc. (NASDAQ:ETRM) Analyst Recommendation Outlook - Clinton Financial - EnteroMedics Inc. (NASDAQ:ETRM) Analyst Recommendation OutlookClinton FinancialCovering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings estimates. There are 2 analysts providing ratings for EnteroMedics Inc. (NASDAQ:ETRM). 2 have given the stock a “Strong Buy”, 0 rate it a “Buy”, ...and more »
04/09/16 11:00 AMCurrent Price Targets For EnteroMedics Inc. (ETRM) - Risers & Fallers - Current Price Targets For EnteroMedics Inc. (ETRM)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of EnteroMedics Inc. (ETRM). The latest broker reports which are currently outstanding on Friday 8th of April state 1 analyst has a rating of “strong buy”, 2 analysts “buy”, ...and more »
04/08/16 11:44 AMEnteroMedics Inc. (NASDAQ:ETRM) Assigned Rating Of 1 - Stocks Daily - EnteroMedics Inc. (NASDAQ:ETRM) Assigned Rating Of 1Stocks DailySell-side analysts hold a positive view on EnteroMedics Inc. (NASDAQ:ETRM) stock. Based on the poll results updated by the Zacks Research as of 2016-04-08, the company's stock has been given 1 rating. This score represents the rating on a scale of 1 to ...and more »
04/07/16 12:10 PMBroker Roundup For EnteroMedics Inc. (ETRM) - Share Trading News - Broker Roundup For EnteroMedics Inc. (ETRM)Share Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of EnteroMedics Inc. (ETRM). According to data from Reuters, 1 analyst has a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold”, 0 analysts ...
04/01/16 12:04 PMENTEROMEDICS INC Financials -
02/17/16 06:40 AMENTEROMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
02/03/16 06:00 AMEnteroMedics to Host Fourth Quarter 2015 Financial Results and Commercialization Update Conference Call - [PR Newswire] - ST. PAUL, Minn., Feb. 3, 2016 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Wednesday, February 17, 2016 at 11:00 AM Eastern Time to discuss financial results for the fourth quarter ended December 31, 2015 and to provide an update on the commercialization of the Company's vBloc® Neurometabolic Therapy. To access the live webcast, visit the events page of the investor relations section of EnteroMedics' website at www.enteromedics.com. EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases.
02/03/16 05:05 AMENTEROMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements an -
About EnteroMedics

EnteroMedics logoEnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Company's initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: ETRM
  • CUSIP: 29365M20
Key Metrics:
  • Previous Close: $0.29
  • 50 Day Moving Average: $0.51
  • 200 Day Moving Average: $1.01
  • P/E Ratio: N/A
  • P/E Growth: -0.63
  • Market Cap: $2.68M
  • Current Quarter EPS Consensus Estimate: $-2.86 EPS
Additional Links:
EnteroMedics (NASDAQ:ETRM) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha